Myeloma minute Carfilzomib
Publicado: Jue Ene 07, 2010 4:01 pm
ASH 2009: David Siegel
PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM); Updated Results From the Bortezomib-Treated Cohort
David Siegel, MD
Hackensack University Medical Center
Hackensack, NJ
http://myeloma.org/ArticlePage.action?t ... goryId=454
Texto.
http://myeloma.org/ArticlePage.action?t ... 98&aTab=-1
abrazos
PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM); Updated Results From the Bortezomib-Treated Cohort
David Siegel, MD
Hackensack University Medical Center
Hackensack, NJ
http://myeloma.org/ArticlePage.action?t ... goryId=454
Texto.
http://myeloma.org/ArticlePage.action?t ... 98&aTab=-1
abrazos